SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to…
FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…
THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…
SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…
FIRST QUARTER IN BRIEF Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30) Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances New preclinical data on naptumomab published EVENTS AFTER THE END OF THE PERIOD Safety and…
Active Biotech’s Annual Report 2022 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.comHans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com About Active Biotech Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is…
FOURTH QUARTER IN BRIEF Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24) Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13) Phase I Multiple dose study of laquinimod recruited final patient OTHER SIGNIFICANT EVENTS JAN…
THIRD QUARTER IN BRIEF Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4) The first part of the multiple dose of laquinimod eye…
SECOND QUARTER IN BRIEF Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26) FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18) Successful completion…
Active Biotech’s Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO,…
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01) First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07) Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9) EVENTS…
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15,2 M. The error has been discovered in connection with the finalization of the Annual…
“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD QUARTER IN BRIEF • Active Biotech provided status update of its clinical naptumomab project on July 5• …
Good progress in the projects towards important clinical events SECOND QUARTER IN BRIEF Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab EVENTS AFTER THE END OF THE PERIOD Active Biotech provided status update on the progress in its clinical naptumomab project Active…
Active Biotech’s Annual Report 2020 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 22, 2021 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO,…
Financing completed and good progress in the projects First quarter in brief Agreement signed for manufacturing of a topical ophthalmic formulation and capsules of laquinimod for use in clinical studies Activities are ongoing according to plan in the naptumomab and tasquinimod projects Corporate Rights issue prospectus published on January 5,…
New strategic R&D plan implemented and financed Fourth quarter in briefTasquinimod The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in December Patent granted in China in October regarding treatment of multiple myeloma…
IMPORTANT EVENTS DURING THE THIRD QUARTERTasquinimod First patient dosed in the monotherapy part of the phase 1b/2a study in multiple myeloma The clinical study design for multiple myeloma will be presented at the virtual American Society of Hematology meeting 2020 in December Patents regarding treatment of acute leukemia granted in…
Second quarter in brief Dr Elaine Sullivan, Dr Aleksandar Danilovski and Dr Axel Glasmacher were appointed as new members of the Board at the Annual General Meeting on May 19 Active Biotech provided status update in the portfolio projects New…
Active Biotech’s Annual Report 2019 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Download as PDF Lund, April 23, 2020 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46…
First quarter in brief Active Biotech announces new direction Patent regarding use of tasquinimod in the treatment of multiple myeloma granted in Japan Events after the end of the period Due to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the…
Significant events during the second quarter In accordance with the Board’s proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company’s property to Estea AB Active Biotech completed the sale of the property, Forskaren 1, to Estea AB on…
PRESS RELEASE Active Biotech’s Annual Report 2018 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Download as PDF Lund, April 26, 2019 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel.…
First quarter in brief Active Biotech’s partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA (“naptumumab”) in combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II study On 1 February 2019, Active Biotech received an indicative, non-binding bid of SEK 275 M for the company’s property from the real…
Fourth quarter in brief Active Biotech communicated updated information about its financial position New data from the LEGATO-HD study presented at the 2018 HSG conference Other significant events during the January-December period Patent regarding tasquinimod for the treatment of multiple myeloma (MM) granted in the US The rights issue in…
Third quarter in brief Active Biotech provides update on laquinimod in Huntington’s disease Active Biotech regains global rights to the development and commercialization of laquinimod Data from the LEGATO-HD study of laquinimod in Huntington’s disease presented at the EHDN meeting Events after the end of the period New data from…
Second quarter in brief The company’s partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago The rights issue in April brought the company SEK 47.1 M Events after the end of the period The company announced that the Phase II LEGATO-HD trial…
First quarter in brief Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018 Patent application for tasquinimod for the treatment of multiple myeloma approved in the US Product patent for the second patent family in the SILC project granted in…
PRESS RELEASE Active Biotech’s Annual Report 2017 is now available för download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, April 23, 2018 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46 192044…
Fourth quarter in brief The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS Patent regarding tasquinimod for the treatment of acute leukemia granted in Europe The process to divest the company’s property in Lund is ongoing On December 7, the company announced…
Third quarter in brief The company’s application related to one of the patent families in the SILC project was granted patent in the US Preclinical data for a SILC substance was published in the scientific journal Cancer Immunology Research The process to divest the company’s research facility at Ideon in…
Second quarter in brief In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate…
Active Biotech’s Annual Report 2016 is now available för download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, May 18, 2017 Tomas LeandersonPresident & CEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46 192044 About Active BiotechActive Biotech…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the pivotal clinical Phase 2 ARPEGGIO study, evaluating…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected…
Active Biotech’s Annual Report 2015 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, April 29, 2016Active Biotech AB (publ) Tomas LeandersonPresident & CEO For further information, please contact:Hans Kolam, CFOTel +46 (0)46 19 20…
Laquinimod· The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017· The clinical Phase 2 study ARPEGGIO for the treatment of…
Laquinimod· In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod’s potential for treatment of primary progressive multiple sclerosis (PPMS)· In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly· In June, it was…
Laquinimod The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017 The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod’s potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington’s disease, are…
· Operations focused on the laquinimod projects and organization adjusted accordingly Laquinimod· The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS) is fully enrolled and results are expected in 2017· The first patient was enrolled for the ARPEGGIO Phase II study, which will evaluate laquinimod’s potential for treatment of primary…
Active Biotech’s Annual Report 2014 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Lund, April 30, 2015Active Biotech AB (publ) Tomas LeandersonPresident & CEO For further information, please contact:Hans KolamCFOTel +46 (0)46 19 20 44 Active Biotech AB(publ) (Nasdaq Stockholm: ACTI) is a…
Laquinimod The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016 Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 Tasquinimod Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk…
Laquinimod · The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016. · In May 2014, EMA’s Committee for Medicinal Products for Human Use (CHMP) announced that the risks observed in animal studies did not prevent registration for treatment in humans. CHMP confirmed its January 2014…
Laquinimod· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting · Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington’s disease· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in…
